Compare Crispr Therapeutics AG (CRSP) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Suncor Energy Inc. — how do they compare? Crispr Therapeutics AG trades at $51.08 (market cap $4.88B), while Suncor Energy Inc. trades at $70.57 (market cap $82.76B). The key difference: Suncor Energy Inc. is far larger — about 17× Crispr Therapeutics AG's market cap, and Suncor Energy Inc. pays a 2.39% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Suncor Energy Inc. for 57 Days on average.
| CRSP | SU | |
|---|---|---|
Market Cap | $4.88B | $82.76B |
Volume | 2,861,747 | 3,832,959 |
Sector | Health | Energy |
52-Week High | $74.92 | $71.87 |
52-Week Low | $44.34 | $38.17 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | $89.29B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Suncor Energy (SU) trades at $68.14, down 0.12% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 12.98, ROE of 19.25%, and consistent earnings beats in recent quarters. Recent news highlights strategic asset sales and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings. Cash flow trends show operational strength with $12.78B from operations in 2025.
SU presents a compelling value opportunity with attractive valuation metrics and robust shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges from weather disruptions. The company's integrated model and international revenue diversification provide stability, though investors should monitor execution under new leadership and global energy market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
